Today: 9 June 2026
South32 share price drops 4% in ASX rout — what investors watch before results
7 February 2026
1 min read

South32 share price drops 4% in ASX rout — what investors watch before results

Sydney, Feb 7, 2026, 17:39 AEDT — The market has wrapped up for the day.

  • South32 dropped 4.1% to close at A$4.41 on Friday, caught up in a sweeping sell-off that hit miners across the ASX.
  • Australian shares just posted their steepest drop since April 2025, putting risk appetite under the microscope heading into Monday.
  • South32 will report its half-year numbers and announce its interim dividend on Feb. 12

Shares of South32 Ltd (S32.AX) slid 4.1% to finish at A$4.41 on Friday, caught up in the risk-off move that dragged Australian miners lower. The stock moved within a range of A$4.37 to A$4.51, ending the session down 19 cents from Thursday’s A$4.60 close.

Markets are closed for now, but South32 lands on traders’ radar ahead of Monday’s session, with investors recalibrating their metals and mining bets. The S&P/ASX 200 closed out the week down 1.81%.

Australian shares took a sharp hit Friday, with the benchmark sliding 2% and nearly A$70 billion wiped from the market—its steepest drop since the April 2025 “Liberation Day” rout, according to ABC’s market blog. “Panic is spreading,” said Michael McCarthy, analyst at MooMoo Australia. He flagged the rare sight of numerous markets tumbling in unison. ABC News

The drop accelerated, Market Index noted, as soft U.S. markets and slumping commodity prices spilled into Australian trade. Materials ended the session deep in the red. Resource-linked names took a beating—coal stocks tumbled, and copper miner Sandfire Resources was among the hardest hit.

South32 operates a mix of mining and metals businesses, with alumina and aluminium sites in Australia, Brazil, South Africa, and Mozambique. The company also holds interests in copper and several other base metals—among them, Chile’s Sierra Gorda and Cannington in Australia—according to an LSEG-sourced company profile on Reuters.

The next big company event is just around the corner. South32 is set to report half-year earnings for the period ended Dec. 31, with the board also making a call on the interim dividend, all slated for Feb. 12 per its official key dates calendar. An interim dividend refers to a distribution to shareholders at the halfway mark of the financial year.

Investors are keyed in for any change in management’s tone on costs, output, or how they characterize demand for their commodity mix. With markets unsettled, even a subtle tweak to guidance has the potential to jolt sentiment.

The macro side’s in play too. South32’s results hinge on metal and bulk commodity prices—moves can come quickly when traders start pulling back risk.

The risk here is straightforward: should global risk appetite continue to wane and metals prices remain choppy, miners often end up trading more like high-beta market proxies than on their own fundamentals. For South32, that spells potential for more abrupt swings, regardless of whether there’s new company-specific news.

Stock Market Today

  • Grab Shares Flat as Singapore Merchant Program and Taiwan Expansion Highlight Growth Focus
    June 9, 2026, 9:28 AM EDT. Grab Holdings' shares on Nasdaq were roughly unchanged at $3.33 in pre-market trading as the company unveiled a new food-and-beverage merchant programme in Singapore and detailed partner commitments in Taiwan. The Singapore initiative, called "Grab Full House Mission," targets smaller merchants with promotions and support to offset rising costs and softer consumer demand. In Taiwan, Grab plans a zero-cost transition and quicker onboarding for delivery partners contingent on regulatory approval of its foodpanda acquisition, marking its first expansion beyond Southeast Asia. Investors are assessing these growth strategies amid regulatory scrutiny, market incentives, and consumer spending pressures.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Xero share price slides 14% in a week — what to watch next for ASX:XRO
Previous Story

Xero share price slides 14% in a week — what to watch next for ASX:XRO

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive
Next Story

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

Go toTop